. Telmisartan increases p-Akt-Ser 473 and p-GSK3β-Ser 9 in hyperglycemic HepG2 cells. HepG2 cells were treated with various doses of telmisartan (0, 10, 20, or 40 M) for 24 h in the presence of 25 mM D-glucose and then with 100 nM insulin for further 10 min. Western blot analyses were performed as described in Fig. 1 . Blots represent at least four experiments. Bar graphs show mean fold alterations above/ below control (±SD). Differences were statistically significant at a) p<0.05, b) p<0.01. GSK3β, glycogen synthase kinase-3β.
